News

Updated results of Phase III trial show darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer

Bayer to help young leaders fight food insecurity

Bayer responds to decision by the Institut national d’excellence en santé et en services sociaux (INESSS) for VITRAKVI® (larotrectinib); reaffirms commitment to Canadian TRK fusion cancer patients

Bayer responds to coverage recommendation by the Pan-Canadian Oncology Drug Review (pCODR) for VITRAKVI® (larotrectinib); reaffirms commitment to Canadian TRK fusion cancer patients

Bayer Fund helps Canadian farmers strengthen rural communities through its Canada’s Farmers Grow Communities Program

4-H Canada and Bayer Renew Five-Year Commitment to Invest in Youth through STEM

Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer